Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2016 Apr 19:12:917-29.
doi: 10.2147/NDT.S88632. eCollection 2016.

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

Cristiana Montemagni  1 , Tiziana Frieri  1 , Paola Rocca  1
Affiliations
Review

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life

Cristiana Montemagni et al. Neuropsychiatr Dis Treat. .

Abstract

Long-acting injectable antipsychotics (LAIs) were developed to make treatment easier, improve adherence, and/or signal the clinician when nonadherence occurs. Second-generation antipsychotic LAIs (SGA-LAIs) combine the advantages of SGA with a long-acting formulation. The purpose of this review is to evaluate the available literature concerning the impact of SGA-LAIs on patient functioning and quality of life (QOL). Although several studies regarding schizophrenia patients' functioning and QOL have been performed, the quantity of available data still varies greatly depending on the SGA-LAI under investigation. After reviewing the literature, it seems that SGA-LAIs are effective in ameliorating patient functioning and/or QOL of patients with schizophrenia, as compared with placebo. However, while methodological design controversy exists regarding the superiority of risperidone LAI versus oral antipsychotics, the significant amount of evidence in recently published research demonstrates the beneficial influence of risperidone LAI on patient functioning and QOL in stable patients and no benefit over oral treatment in unstable patients. However, the status of the research on SGA-LAIs is lacking in several aspects that may help physicians in choosing the correct drug therapy. Meaningful differences have been observed between SGA-LAIs in the onset of their clinical efficacy and in the relationships between symptoms and functioning scores. Moreover, head-to-head studies comparing the effects of SGA-LAIs on classical measures of psychopathology and functioning are available mainly on risperidone LAI, while those comparing olanzapine LAI with other SGA-LAIs are still lacking. Lastly, some data on their use, especially in first-episode or recent-onset schizophrenia and in refractory or treatment-resistant schizophrenia, is available.

Keywords: first-episode schizophrenia; outcome; recent-onset schizophrenia; treatment resistant schizophrenia.

PubMed Disclaimer

References

    1. Mathers C, Boerma T, Fat DM. The Global Burden of Disease: 2004 Update. Geneva: World Health Organization; 2008. [Accessed November 1, 2012]. Available from: http://www.who.int/healthinfo/global_burden_disease/GBD_report_2004updat....
    1. Murray CJ, Lopez AD. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press on behalf of the World Health Organization and the World Bank; 1996. p. 990.
    1. Bond GR. Supported employment: evidence for an evidence-based practice. Psychiatr Rehabil J. 2004;27:345–359. - PubMed
    1. Lehman AF. Vocational rehabilitation in schizophrenia. Schizophr Bull. 1995;21:645–656. - PubMed
    1. Hatfield B, Huxley P, Mohamad H. Accommodation and employment: a survey into the circumstances and expressed needs of users of mental health services in a northern town. Br J Soc Work. 1992;22:61–73.